What Intermezzo Treats: Main Uses and Benefits

---

The therapeutic application of Intermezzo (zolpidem sublingual) is used to address specific symptomatic patterns in adult patients experiencing sleep disturbances. This product is relevant for addressing the symptomatic need to return to sleep after an awakening.

Targeting Sleep Maintenance Insomnia

This medication is generally relevant in contexts where the patient is experiencing a specific form of insomnia marked by middle-of-the-night awakening. It is applied when a full night's sleep is interrupted and the patient subsequently faces difficulty returning to the sleeping state. It is relevant for providing short-term support for sleep continuity after an unplanned interruption, which is used in situations involving certain distressing symptoms.

The relevant indications involve managing wakefulness after sleep onset (WASO) and difficulty returning to sleep during the night. The medication is commonly used when supportive symptom management is appropriate for these episodic manifestations.

“The use case is assisting patients with the return to sleep when they find themselves awake well before their planned waking time.”

---

Symptomatic Relief for Nocturnal Wakefulness

Intermezzo is commonly used for the symptomatic management of WASO, which represents the duration of time spent awake. By addressing this symptom, which can create noticeable functional strain, on an as-needed basis, the medication generally assists with facilitating the re-initiation of sleep. This supports the easing of the duration of time the patient remains awake and may assist with maintaining the remaining sleep duration, contributing to easing distress during symptomatic periods.

Quick Fact: Relief for Nocturnal Wakefulness This medication provides supportive relief primarily for episodes of wakefulness that occur after initial sleep, supports general well-being by assisting with the easing of time spent awake during the night.

Eligibility and Contraindications for Intermezzo

Official regulatory documents define specific populations who can and cannot use Intermezzo (zolpidem sublingual tablet). The medicine is officially indicated only for Adults (18 years and older) who wake in the middle of the night and have at least four hours of bedtime remaining before their planned waking time. Safety and effectiveness are not established in pediatric patients.

Absolute Non-Eligibility (Contraindications)

Use of Intermezzo is contraindicated (absolutely prohibited) for individuals with a known hypersensitivity to zolpidem or who have a history of complex sleep behaviors (such as sleepwalking or sleep-driving) after taking zolpidem. Furthermore, EU labeling lists severe hepatic insufficiency (severe liver failure), sleep apnoea syndrome, and myasthenia gravis as absolute contraindications.

Restricted Use Populations

Specific populations are eligible but require conditional use, often restricting them to the lowest strength (1.75 mg). This applies to geriatric patients (65 years and older), patients with non-severe hepatic impairment, and patients taking other CNS depressants. Use during pregnancy is advised against, as animal data suggests a risk of fetal harm. Zolpidem is excreted in breast milk, requiring cautious use in nursing mothers.

Interactions with other medicines and products

Intermezzo’s interaction profile is categorized by its potential for Pharmacodynamic (PD) Potentiation and Pharmacokinetic (PK) Modulation by other substances.

Pharmacodynamic Interactions and Prohibitions

Co-administration with any Central Nervous System (CNS) depressant, including opioids, tricyclic antidepressants (such as Imipramine), and antipsychotics (such as Chlorpromazine), results in additive CNS-depressant effects, including heightened sedation and impaired alertness. Use with alcohol (ethanol), other sleep aids, or any other zolpidem product is prohibited due to this additive risk. Contraindications are also noted for patients with a history of complex sleep behaviors.

Metabolic (PK) Interactions

The medicine is primarily metabolized by the CYP3A4 enzyme system. Co-administration with CYP3A4 inducers (e.g., Rifampin) reduces zolpidem plasma exposure and lessens its effect. Conversely, CYP3A4 inhibitors (e.g., Ketoconazole) increase zolpidem exposure and enhance its effect. The herbal product St. John's Wort may also decrease the drug's effect.

Administration Restrictions

To mitigate the risk of residual impairment, a mandatory timing rule requires Intermezzo to be taken only when a patient has at least four hours of planned sleep remaining before waking. Administration with or immediately after a meal is restricted because it officially slows the absorption rate, delaying the onset of the intended effect. Use is formally avoided in patients with severe hepatic impairment due to the risk of reduced clearance leading to increased exposure.

Targeting GABA Receptors to Boost CNS Inhibition

This drug acts as a positive allosteric modulator of the GABA-A receptor complex, specifically targeting receptors containing the alpha1 subunit in the brain's central nervous system (CNS). This molecular interaction enhances the activity of the inhibitory neurotransmitter GABA (gamma-aminobutyric acid). By promoting GABA's effect, the flow of negatively charged chloride ions into the post-synaptic neuron is increased. This action dampens neural excitability through a process called hyperpolarization.

---

The Cascade to Transient Sedation

The widespread increase in inhibitory signaling generates a rapid cascade of central nervous system depression, thereby lowering the overall level of CNS activity. The specific formulation is designed for rapid absorption followed by subsequent fast metabolic clearance in the liver. This pharmacokinetic profile ensures that the resulting physiological change—the sedative effect—is notable but short-lived, reflecting the transient nature of the mechanistic effect on neural signaling.

How Intermezzo is Used: Official Administration Guidelines

Intermezzo (zolpidem sublingual tablet) is strictly administered according to specific procedural and dosing guidelines. The medication is designated for as-needed use, taken only once per night to address an episode of middle-of-the-night awakening. Crucially, the dose must not be taken unless the patient has a minimum of four hours of bedtime remaining before their planned time of waking, a core restriction for its appropriate use.

The approved route of administration is sublingual. The tablet must be placed under the tongue and allowed to disintegrate completely, and it should not be swallowed whole. To ensure rapid absorption, the administration should ideally not occur with or immediately after a meal.

Official dosing is differentiated based on both sex and age. The single recommended dose for adult men under 65 is 3.5 mg. The standard recommended dose for adult women under 65 is lower at 1.75 mg. A lower dose of 1.75 mg is also the recommended dose for all older adults (over 65) and for patients with known hepatic impairment, regardless of sex. The dose should not be readministered during the same night under any circumstances.

This structured usage protocol ensures that the quick-acting sublingual form is applied exclusively within the narrow, context-specific conditions defined for its use.

Research Evidence / Overview of Studies for Intermezzo

Evidence for Use in Middle-of-the-Night Awakening

Intermezzo was studied in research exploring how symptoms change over time for individuals experiencing a middle-of-the-night awakening followed by difficulty returning to sleep. The trials monitored objective sleep measures in controlled sleep lab settings using Polysomnography (PSG), as well as patient-reported outcomes gathered through sleep diaries. Research examined the time required for sleep re-initiation following a dose taken after waking up.

Studies reported measurements of the time it took for the observed populations to re-initiate sleep, and these measurements were evaluated against placebo. Research specifically examined the difference in re-initiation time between the sublingual tablet and a placebo, which was the focus of the primary efficacy research.

---

Methods Used to Study Sleep Outcomes

The primary evidence was evaluated in controlled research scenarios using both Objective measurements from PSG to track physiological changes related to the re-initiation of sleep, and patient-reported outcomes to evaluate perceived discomfort. These studies allowed researchers to explore short-term symptom changes reliably under highly structured conditions.

---

Research Gaps and Specific Adult Patient Groups

The evidence contributes to the broader evidence landscape but is primarily associated with short-term outcomes, typically gathered over a few weeks of use. Data for certain groups remain insufficient when considering outcomes beyond this initial period, meaning long-term effects are not fully established. Some studies observed findings related to pharmacokinetic differences between male and female subjects. In contrast, data for certain groups, such as older adults or those with underlying medical conditions, remain insufficient within the core clinical trials, and certainty remains low in these populations.

---

What Remains Uncertain About the Research

Follow-up durations were limited in the main efficacy trials. This means that certainty remains low regarding the long-term effects of using this fast-acting formulation. Additionally, subgroup findings are uncertain for those with limited remaining sleep time, leading to specific guidelines established by regulatory bodies. This medication was studied for a narrow, specific use case—middle-of-the-night awakening—and research does not determine whether an individual with a different type of sleep difficulty will respond similarly.

Common questions about Intermezzo (FAQ)

---

Q: What should I do with unused or expired tablets that I no longer need?

According to official regulatory guidance, the preferred way to dispose of unused or expired tablets is through a formal drug take-back program. If no take-back program is available, the tablets should be mixed with an undesirable substance (like coffee grounds or cat litter), sealed in a container, and placed in the household trash. The medication is generally not recommended to be flushed down the toilet.

---

Q: Why is the recommended dose different for men and women?

Official prescribing information indicates that the initial recommended dose is lower for adult women than for adult men. This difference is based on clinical studies showing that women tend to clear the medication from their bodies more slowly. This slower clearance is a regulatory concern for next-day impairment if women were to take the higher dose, as studies found they tend to have higher morning concentrations.

---

Q: Does this medicine interact with St. John's Wort?

Regulatory documents list the herbal product St. John's Wort as a substance that may decrease the overall effectiveness of Intermezzo. This is thought to occur because St. John's Wort can affect the activity of the CYP3A4 enzyme, which is responsible for breaking down the medication, which can potentially lower the drug concentration in the body.

---

Q: How is Intermezzo different from other sleep medications, like regular Ambien (immediate-release zolpidem)?

The official indication for Intermezzo is very specific: it is used as-needed to help patients address difficulty returning to sleep when they wake up in the middle of the night. This fast-acting sublingual formulation is not intended for people who need help falling asleep at the beginning of the night, which is a common indication for other types of immediate-release zolpidem products.

---

Q: Will I build up a tolerance to this medication over time?

Intermezzo is regulated as a Schedule IV controlled substance, which reflects regulatory concern regarding its potential for abuse and dependence. Clinical trials primarily focused on short-term outcomes. Due to the focus on short-term outcomes in core trials, certainty remains low regarding the long-term development of effects like tolerance.

---

Q: How soon after taking the tablet should I start to feel sleepy?

The sublingual tablet is designed for rapid absorption to address difficulty returning to sleep after an awakening. Clinical studies evaluated the drug's effectiveness by measuring the reduction in the time it took for participants to re-initiate sleep. However, official product information does not specify a precise time frame for when an individual patient should begin to feel the sedative effect.

---

Q: What is the full list of inactive ingredients in Intermezzo tablets?

Yes, the full list of inactive ingredients is formally listed in the Description section of the official regulatory prescribing information for the product.

How to Store and Dispose of Intermezzo

Intermezzo (zolpidem tartrate) sublingual tablets must be stored at Controlled Room Temperature, defined as 68 F to 77 F (20 C to 25 C). The medication must be protected from moisture and kept away from direct light and freezing temperatures.

Storage Requirements

Storage Condition	Requirement
Temperature Range	68 F to 77 F
Environmental Rules	Protect from moisture; Keep from freezing
Packaging Rules	Only open the unit-dose pouch when ready to use

As a Schedule IV controlled substance, Intermezzo must be kept in a safe place to prevent misuse and stored out of reach of children.

Disposal

Unused or expired Intermezzo should ideally be disposed of using a drug take-back program. If a take-back option is unavailable, the tablets must be mixed with an undesirable substance (such as coffee grounds or cat litter) and placed in a sealed container before discarding in the household trash. The product is not recommended for flushing.